Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238211 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT01238211 is a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 61 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT01238211, a Phase 2 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with dasatinib may kill more cancer cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cytarabine
- DRUG Dasatinib
- DRUG Daunorubicin Hydrochloride
Study Locations (20)
Illinois
- Saint Joseph Medical Center - Bloomington
- Illinois CancerCare-Bloomington - Bloomington
- Graham Hospital Association - Canton
- Illinois CancerCare-Canton - Canton
- Memorial Hospital - Carthage
- University of Illinois - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
- Heartland Cancer Research NCORP - Decatur
- Eureka Hospital - Eureka
- Illinois CancerCare-Eureka - Eureka
- Illinois CancerCare-Galesburg - Galesburg
- Mason District Hospital - Havana
- Illinois CancerCare-Macomb - Macomb
- Mcdonough District Hospital - Macomb
- Bromenn Regional Medical Center - Normal
- Carle Cancer Institute Normal - Normal
- Illinois CancerCare-Community Cancer Center - Normal
Delaware
- Beebe Medical Center - Lewes
- Christiana Care Health System-Christiana Hospital - Newark
Florida
- AdventHealth Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-12-14 |
| Est. Completion | 2021-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01238211
The ClinicalTrials.gov registry entry for NCT01238211 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (47% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01238211 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Delaware, Florida.
Frequently Asked Questions
What is clinical trial NCT01238211 about?
NCT01238211 is a clinical study titled "Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the ...
What is the current status of trial NCT01238211?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2010-12-14. Estimated completion is 2021-03-15.
What conditions does trial NCT01238211 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11.
What interventions are being tested in trial NCT01238211?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Dasatinib (DRUG), Daunorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01238211?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01238211 being conducted?
This trial has 20 study locations across Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Acute Myeloid Leukemia
All registered trials for this condition
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
All registered trials for this condition
Delaware
All trials with a study site in Delaware
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.